Jim Cramer
Bargain hunting: These 8 portfolio stocks look quite cheap, but only some are worth buying
The holiday shopping season has come and gone. When it comes to stock picking, at least, the desire to find a bargain is as strong as ever. A recent analysis of our portfolio revealed we own more than a couple cheap stocks, including one of our newer additions in Bristol Myers Squibb . Still, we’re […]
Read More
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a […]
Read More
Eli Lilly looks to extend its winning streak over the broader market to 6 years
Eli Lilly has outperformed the S & P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question. Year-to-date performance: Up 33.7% Forward price-to-earnings ratio: 34.3 versus five-year average of 34.5 Our rating: Buy-equivalent 1 Our price target: […]
Read More
Jim Cramer explains how to spot ‘exquisite moments’ like Friday’s session
CNBC’s Jim Cramer reviewed Friday’s market action, dubbing the session an “exquisite moment,” where stocks opened weak, but the averages climbed by the close. While he said this particular moment has come and gone, he listed ways investors can recognize one in the future, saying these conditions can yield big gains. “We used to call […]
Read More
FedEx CEO touts company’s ‘scaled network’ as supply chain challenges loom with Trump presidency
In a Thursday interview with CNBC’s Jim Cramer, FedEx CEO Raj Subramaniam said his company can do well even if there is a supply chain shakeup. “As the supply chain patterns change, we are here, there and everywhere,” he said. “That’s the advantage people sometimes miss, the fact that we have a scaled network in […]
Read More
After taking morning profits, we’re afternoon buyers of 2 stocks in an oversold market
We’re buying 25 shares of Home Depot at roughly $407 each and 14 shares of Blackrock at roughly $1,041. Following Tuesday’s trades, Jim Cramer’s Charitable Trust will own 200 shares of HD, increasing its weighting to 2.25% from about 2%. The Trust portfolio, used by the CNBC Investing Club, will own 75 shares of BLK […]
Read More
We’re adding to our position in a stock that just landed a big Wall Street endorsement
Shortly after the opening the bell, we will be buying 300 shares of Bristol Myers Squibb at roughly $56.50. Following the trade, Jim Cramer’s Charitable Trust will own 1,200 shares of BMY, increasing its weighting in the portfolio to roughly 1.9% from about 1.4%. Wall Street’s stretch of bad breadth may have finally caught up […]
Read More
We want to boost our ownership of a portfolio stock that just boosted its dividend
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Thursday markets: Stocks are taking a breather after Wednesday’s big surge, especially in the Nasdaq Composite and the more narrow “Magnificent Seven” cohort. The yield on […]
Read More
Here are 7 key moments from Jim Cramer’s interview of Donald Trump from the NYSE
President-elect Donald Trump told CNBC’s Jim Cramer on Thursday the stock market is “going to see a lot of good days ahead.” Jim interviewed Trump on the floor of the New York Stock Exchange moments after the president-elect rang the opening bell. In their wide-ranging discussion, Trump said the performance of the stock market is […]
Read More
Eli Lilly’s obesity drug beats rival in head-to-head trial — where Cramer sees shares going next
New trial data has cemented Club holding Eli Lilly ‘s pole position in the highly competitive obesity drug race. The news Eli Lilly’s obesity drug Zepbound bested its main rival Wegovy — made by Denmark’s Novo Nordisk — in the first head-to-head trial comparing the fast-growing weight loss treatments. Patients on Zepound lost an average […]
Read More